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Pregnancy places increased demands on the mother to provide adequate nutrition to the growing conceptus. A number of
micronutrients function as essential cofactors for or themselves acting as antioxidants. Oxidative stress is generated during normal
placental development; however, when supply of antioxidant micronutrients is limited, exaggerated oxidative stress within both
the placenta and maternal circulation occurs, resulting in adverse pregnancy outcomes. The present paper summarises the current
understanding of selected micronutrient antioxidants selenium, copper, zinc, manganese, and vitamins C and E in pregnancy. To
summarise antioxidant activity of selenium is via its incorporation into the glutathione peroxidase enzymes, levels of which have
been shown to be reduced in miscarriage and preeclampsia. Copper, zinc, and manganese are all essential cofactors for superoxide
dismutases, which has reduced activity in pathological pregnancy. Larger intervention trials are required to reinforce or refute a
beneficial role of micronutrient supplementation in disorders of pregnancies.
1. Introduction
1.1. Nutrition in Pregnancy. The importance of proper
nutrition prior to and throughout pregnancy has long been
known for optimising the health and well-being of both
mother and baby [1]. Pregnancy is a period of increased
metabolic demands with changes in a women’s physiology
and the requirements of a growing fetus [2, 3]. Insuﬃcient
supplies of essential vitamins and micronutrients can lead
to a state of biological competition between the mother
and conceptus, which can be detrimental to the health
status of both [4] Deficiency of trace elements during
pregnancy is closely related to mortality andmorbidity in the
new born [5]. Deficiencies of specific antioxidant activities
associated with the micronutrients selenium, copper, zinc,
and manganese can result in poor pregnancy outcomes,
including fetal growth restriction [6], preeclampsia [7]
and the associated increased risk of diseases in adulthood,
including cardiovascular disease and type 2 diabetes [8–11].
A large body of research has investigated the role of
macronutrients in pregnancy and especially the eﬀects of
both maternal under and over nutrition on the long-term
health of the oﬀspring [12, 13]. A number of hypotheses
have been suggested to explain the contribution of maternal
nutrition during the fetal and embryonic periods and the
programming of the cardiovascular and metabolic system
of the oﬀspring [14, 15]. In addition to the contribution
of macronutrition to successful pregnancy more recently
studies have begun to focus on the role of essential specific
micronutrients, so called because they are an absolute re-
quirement and are required in only small amounts daily [16].
The pregnant mother must provide a source of nourish-
ment and gaseous exchange to enable maximal embryonic
and fetal growth to occur, whilst at the same time preparing
her body for labour and parturition and the later demands
of lactation. In addition a careful balance must be main-
tained between providing immune surveillance to protect
the mother from infection and whilst at the same time
allowing the implantation and survival of the semiallogenic
conceptus [17, 18]. The development and establishment of
the placenta and its circulatory system is crucial in the
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Figure 1: Diagram of the maternal fetal interface in early pregnancy. Extravillous cytotrophoblast cells migrate away from the cell column
of the anchoring villus and invade through the maternal deciduas and inner third of the myometrium in order to gain access to maternal
blood supply via maternal spiral arteries. Transformation of the maternal spiral arteries occurs as endovascular trophoblast help convert the
endothelial cells lining the arteries into an amorphous fibrinoid matrix which is unresponsive to vasoactive stimuli and serves to enlarge the
vascular lumen maximising blood supply to the intervillous space.
successful maintenance of maternal health and also enabling
development of the embryo and growth of the fetus.
The establishment of the fetoplacental circulation re-
quires the invasion of placental derived extravillous tro-
phoblast from anchoring cytotrophoblast columns through
the maternal decidua and into the maternal spiral arteries
(Figure 1). During the first 8 weeks of pregnancy, trophoblast
plugs within the spiral arteries which exist to protect embry-
onic DNA from damage by oxidative stress [19] are released
allowing the onset of placental circulation (Figure 1). The
release of trophoblast plugs with flow of blood into the
intervillous space leads to the generation of oxidative stress
[20]. However, the placenta is armed with antioxidant
defences, including the selenium-dependent glutathione
peroxidases, thioredoxin reductases, selenoprotein-P, and
copper/zinc and manganese superoxide dismutases (Cu/Zn
and Mn SODs) (Figure 2), which protect the placenta from
any undue harm [21–24]. As the extravillous trophoblast
cells migrate through the spiral artery wall, they are involved
in the process of physiological conversion, which serves to
enlarge the vessel lumen thereby maximising blood supply to
the intervillous space, enabling maximal perfusion of nutri-
ents and gases through the placental syncytiotrophoblast.
Deficient extravillous trophoblast invasion is associated with
reduced spiral artery remodelling leading to reduced blood
flow and increased oxidative stress within the placenta and is
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Figure 2: Major pathways of reactive oxygen species generation and metabolism. Superoxide can be generated by specialised enzymes, such
as the xanthine or NADPH oxidases, or as a byproduct of cellular metabolism, particularly the mitochondrial electron transport chain.
Superoxide dismutase (SOD), both Cu/Zn and Mn SOD, then converts the superoxide to hydrogen peroxide (H2O2) which has to be rapidly
removed from the system. This is generally achieved by catalase or peroxidases, such as the selenium-dependent glutathione peroxidases
(GPxs) which use reduced glutathione (GSH) as the electron donor.
known to be the primary defect occurring in preeclampsia
[25, 26], fetal growth restriction [27, 28], and sporadic
miscarriage [29]. Additionally, preeclampsia has also been
associated with reduced levels of antioxidant enzyme protec-
tion causing further placental damage [30–32].
The pathogenesis of adverse pregnancy outcomes includ-
ing preeclampsia and fetal growth restriction [33] and a
number of neonatal outcomes [34] has been shown to
be associated with oxidative stress. Preeclampsia (de novo
proteinuric hypertension) is estimated to occur in ∼3%
of all pregnancies and is a leading cause of maternal and
perinatal mortality and morbidity in the Western world
[35, 36]; together with other hypertensive disorders of
pregnancy, preeclampsia is responsible for approximately
60,000maternal deaths each year [37] and increases perinatal
mortality five-fold [38]. Optimal outcome for the mother
and child often dictates that the infant is delivered early
leading to increased preterm delivery and low infant birth
weight rates. Placental and maternal systemic oxidative stress
are components of the syndrome [39] and contribute to a
generalised maternal systemic inflammatory activation [40].
Placental ischaemia-reperfusion injury has been implicated
in excessive production of ROS, causing release of placental
factors that mediate the inflammatory responses [41].
Fetal growth restriction is associated with increased
perinatal mortality and morbidity [42]. The mechanisms
are still to be elucidated but a likely factor is placental
ischemia/hypoxia [43], but it is thought that ischemia-
reperfusion injury may contribute to the oxidative stress
and could result in the release of reactive oxygen species
into the maternal circulation possibly resulting in oxidative
DNA damage and may underlie development of fetal growth
restriction [44].
The current paper focuses specifically on those micronu-
trients which are associated with antioxidant activity due
to the importance of oxidative stress in both normal
pregnancy and pathological pregnancy outcomes. However,
it is important to highlight that other micronutrients are also
important in pregnancy [16] but are outside the scope of the
current paper.
2. Methods
A number of micronutrients and vitamins are known to
serve as antioxidants or be essential cofactors for antioxidant
enzymes; these include selenium, copper, zinc, manganese,
and vitamins C and E. The present paper summarises current
understanding of the importance of these micronutrient
antioxidants in pregnancy. For this paper, we included data
and relevant information obtained through a search of
the PubMed database using free text and Medical Subject
Headings terms for all articles published in English from
1971 through 2011 which included the term “selenium,”
“zinc,” “copper,” “manganese,” “vitamin E and C,” and one of
the following: “pregnancy,” “preeclampsia,” or “fetal growth
restriction.” We further included published and unpublished
data from our own laboratories and an “in-house” library
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Table 1: Requirement of micronutrient intakes for selenium, copper, zinc, manganese, vitamin C, and vitamin E.
Selenium (μg/d) Copper (μg/d) Zinc (mg/d) Manganese (mg/d) Vitamin C (mg/d) Vitamin E (μg/d)
RDA1
Female
adult
55 900 8 1.8 75 15
Pregnancy 60 1,000 11 2 85 15
Upper limit 400 10,000 40 — 2,000 1,000
RNI2
Female
adult
60 1,200 7 1.4 40 —
Pregnancy 75 1,500 7 — 50 —
NR3
Female
adult
30 1,350 1 — — —
Pregnancy — 1,150 2 — — —
RDA: recommended dietary allowance; RNI: reference nutrient intakes; NR: normative requirement estimate. Values taken from 1Institute of Medicine [77,
79], 2Department of Health [80], and 3WHO/FAO/IAEA [81].
of relevant publications. The procedure was concluded by
the perusal of the reference sections of all relevant studies
or reviews, a manual search of key journals and abstracts
from the major annual meetings in the field of pregnancy,
and nutrition and contact with experts on the subject, in an
eﬀort to identify relevant unpublished data.
2.1. Selenium. Selenium is incorporated into proteins to
make selenoproteins, including the glutathione peroxi-
dase antioxidant enzymes, thioredoxin reductases, and
selenoprotein-P [45]. In addition, selenium is essential
for the production of active thyroid hormones and is
essential for normal thyroid function [46]. Maternal sele-
nium concentrations and glutathione peroxidase activity fall
during pregnancy (selenium concentrations in 1st trimester:
65 μg/L; 3rd trimester: 50 μg/L) [47, 48]. Worldwide diﬀer-
ences exist in assessment of selenium requirements, ade-
quacy, and intakes (Table 1). Most of these values have been
determined from the intake believed necessary to maximise
the activity of the antioxidant glutathione peroxidase in
plasma [49, 50] and selenium, like vitamins C and E
which have received much attention in recent years. It has
been observed that babies on average have lower selenium
concentrations compared to the mother (maternal selenium
58.4 μg/L; umbilical cord selenium: 42.1 μg/L) [32, 51],
which is expected as selenium is transported via the placenta
across a concentration gradient via an anion exchange
pathway, shared with sulphate [52, 53].
Recurrent early pregnancy loss has been associated
with reduced serum selenium concentrations compared to
healthy controls in two observational studies from UK
(mean± SD: 54± 19 versus 76± 14 μg/L, resp.) [54] and
Turkey (55± 17 versus 81± 16 μg/L, resp.) [55]. It has
therefore been suggested that reduced selenium concen-
tration results in reduced glutathione peroxidase activity
culminating in reduced antioxidant protection of biological
membranes and DNA during the early stages of embryonic
development [54, 56]. Although speculative, and requiring
larger placebo-controlled randomised trials, women with
recurrent early pregnancy lossmay benefit from optimisation
of selenium status.
Recently, our group and others have demonstrated,
through retrospective studies, the association between low
serum selenium concentrations and reduced antioxidant
function of the associated antioxidant glutathione peroxidase
enzymes in women with preeclampsia (defined a de novo
proteinuric hypertension) [32, 57, 58]. It has been suggested
that adequate selenium status is important for antioxidant
defence and may be a potential factor in women at risk of
preeclampsia; this hypothesis has been further justified by the
reduced expression and activities of glutathione peroxidase
found in maternal, fetal, and placental samples taken from
25 preeclamptic pregnancies, when compared to 27 normal
controls in our recent cross-sectional retrospective study
[32]. Dawson et al. also completed a retrospective study
in the USA and reported lower amniotic fluid selenium
concentrations in 29 preeclamptics delivering between 33-
and 36-week gestation compared to 48 gestation-matched
controls (10± 1 versus 7± 0.7 μg/L, resp.) [59].
Fetal growth restriction or delivery of a small for
gestational age (SGA) is defined as an individualised birth
weight ratio below the 10th percentile [42]. Reports of sele-
nium concentrations with regards to fetal growth restriction
are inconsistent. A retrospective study had reported low
placental selenium concentrations in 49 mothers aﬀected
by fetal growth restriction, compared to 36 healthy normal
birth weight controls [60], whereas others have reported
higher [61, 62] or unchanged concentrations [63]. Another
retrospective study also demonstrated in 81 SGA babies,
infant plasma selenium concentrations to be significantly
lower compared to controls [64]. A recent retrospective study
by our group on an adolescent cohort [65] found lower
maternal plasma selenium concentrations on 28 mothers
who delivered SGA babies compared to 143 healthy controls
[66]. Further studies are warranted to fully investigate the
potential link between selenium deficiency and fetal growth
restriction.
Only a small number of selenium supplementation
trials during pregnancy have been carried out to date. A
prospective, randomised, placebo-controlled study of se-
lenium supplementation during and after pregnancy in
pregnant women positive for thyroid peroxidase antibodies
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(TPOAb(+)) who are prone to develop postpartum thy-
roid dysfunction (PPTD) and permanent hypothyroidism
found that supplementation with 200 μg/d selenomethionine
significantly reduced the incidence of PPTD and permanent
hypothyroidism [67]. The authors concluded that selenium
supplementation during pregnancy and in the postpartum
period reduced thyroid inflammatory activity and the inci-
dence of hypothyroidism, possibly by increasing the seleno-
proteins glutathione peroxidase or iodothyronine deiodinase
activities, thereby contributing in part, to counterbalance the
postpartum immunological rebound [67].
To date there have been a couple of small placebo-
controlled randomised control trials on selenium supple-
mentation, reporting lower rates of preeclampsia and/or
pregnancy-induced hypertension in the supplemented
groups [68–70]. It must be noted that neither of these
studies adequately addressed the role of supplementation
on the incidence of preeclampsia. Currently, the “Selenium
in Pregnancy Intervention Trial” (SPRINT) is underway
in the UK, jointly by the University of Surrey and Oxford.
This is a small randomised controlled trial of selenium
supplementation (60 μg a day). It is not powered to
demonstrate clinical benefit but will provide insight in-
to the impact of selenium supplements on laboratory
measurements of circulating factors that are relevant to the
development of preeclampsia. If this is successful, a much
larger multicentre trial will be needed to analyse clinical
benefit.
2.2. Copper. Copper is an essential cofactor for a number
of enzymes involved in metabolic reactions, angiogene-
sis, oxygen transport, and antioxidant protection, includ-
ing catalase, superoxide dismutase (SOD) (Figure 2) and
cytochrome oxidase [71]. During pregnancy, plasma copper
concentrations significantly increase, returning to normal
nonpregnant values after delivery (Mean± SD–1st trimester:
147.6± 34.6; 3rd trimester: 204.2± 41.8 μg/L) [72–74]. The
increase in copper with progression of pregnancy could
be partly related to synthesis of ceruloplasmin, a major
copper-binding protein, due to altered levels of oestrogen
[74]. Approximately 96% of plasma copper is strongly
bound to ceruloplasmin [75], a protein with antioxidant
ferroxidase properties [75, 76]. The dietary intake of copper
in women aged between 19 and 24 years is generally below
the recommended levels (Table 1) [77] which may cause
problems during pregnancy when requirements increase
[78].
Copper is essential for embryonic development [82].
Maternal dietary deficiency can result in both short-term
consequences, including early embryonic death and gross
structural abnormalities, and long-term consequences such
as increased risk of cardiovascular disease and reduced
fertilisation rates [71, 83]; current recommendations on
intakes are summarised in Table 1. Severe copper deficiency
can lead to reproductive failure and early embryonic death
[84], whereas mild or moderate deficiency has little eﬀect on
either the number of live births or neonatal weight [85].
Cu/Zn SOD is an important antioxidant known to be
expressed in both maternal and fetal tissues [86]. Copper
concentration has been shown to be higher in maternal
plasma than in umbilical cord plasma [87–89]. It has
been suggested that the placenta acts as a blockade in the
transfer of copper from the mother to the fetus [89, 90].
A recent observational Turkish study on 61 placentae from
healthy pregnancies between 37- and 40-week gestation
found that copper concentrations positively correlated with
neonatal weight; the authors suggested that copper may
have interactive connections in human placenta [91] and
this requires further studies to fully elucidate its role. It is
known that copper is transferred across the placenta via high-
aﬃnity copper transporter (CTR1) and has been shown to
be expressed early in pregnancy, and it is also thought that
placental copper transport is related to iron transport but the
mechanism is unknown [78].
A small retrospective study in the 1980s reported
increased placental copper concentrations in 8 preeclamptic
women compared to 10 controls (53 versus 124 μg/Kg, resp.),
suggesting that this increase in preeclampsia maybe an
exaggerated response of normal pregnancies [92]. Further
retrospective studies from Turkey have shown elevation of
maternal serum copper levels in preeclampsia after clinical
onset of the disease compared to controls (mean± SD:
159± 38 versus 194± 52 μg/L, resp.) [93, 94]. Moreover,
increased amniotic fluid copper concentration from 19
preeclamptic women compared to 53 controls has also been
reported (mean± SD: 19± 5 versus 29± 3 μg/L, resp.) [59].
It is thought that as copper is a redox-active transition
metal and can participate in single electron reactions and
catalyse the formation of free radicals, including undesirable
hydroxyl radicals, it could contribute to oxidative stress char-
acteristic of preeclampsia [93]. This illustrates that copper
itself appears to act as a pro-oxidant, but when associated in
Cu/Zn SOD functions as an antioxidant. Furthermore, stud-
ies have reported increased levels of serum ceruloplasmin
in women with preeclampsia; this positively correlated with
serum malondialdehyde, suggesting an increased production
of this antioxidant protein in response to increased lipid
peroxidation [93, 95, 96], although further studies are
required to confirm this hypothesis. However, it must be
remembered that concentrations early in pregnancy have yet
to be determined and data on copper status in normal human
pregnancies are sparse. This is further hampered by the fact
that at present there is no reliable biomarker for copper
status, so whether deficiency is a significant public health
problem remains unclear [97].
2.3. Zinc. Zinc is an essential constituent of over 200
metalloenzymes participating in carbohydrate and protein
metabolism, nucleic acid synthesis, antioxidant functions
(through Cu/Zn SOD; Figure 2), and other vital functions
such as cellular division and diﬀerentiation, making it
essential for successful embryogenesis. [72]. It was estimated
in 2002 by the World Health Organisation that suboptimal
zinc nutrition eﬀected nearly half the world’s population
[98]. During pregnancy, zinc is also used to assist the fetus
to develop the brain and also to be an aid to the mother
in labour [99]. It has been estimated that the total amount
of zinc retained during pregnancy is ∼100mg [100]. The
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requirement of zinc during the third trimester is approxi-
mately twice as high as that in nonpregnant women [81].
Plasma zinc concentrations decline as pregnancy progresses
(mean± SD–1st trimester: 71.3± 12.9 μg/L; 3rd trimester:
58.5± 11.5 μg/L) [72, 74, 101, 102]. In addition, a nutrition
analysis revealed that in pregnant women the everyday diet
intakes include not more than 50% of the daily requirement
of zinc [103].
Alteration in zinc homeostasis may have devastating
eﬀects on pregnancy outcome, including prolonged labour,
fetal growth restriction, or embryonic or fetal death [104].
Zinc is a trace element with a great importance for fetal
growth restriction where it is used in order to improve
fetal growth [72]. Goldenberg et al. completed a randomised
double-blind placebo-controlled trail of zinc supplemen-
tation (25mg per day) during pregnancy from 19-week
gestation in African-American women (294 in supplemented
and 286 in placebo group). Those given zinc supplemen-
tation had a significantly greater birth weight and head
circumference compared to the placebo group highlighting
the importance of adequate zinc supply during pregnancy
[105]. A limitation of many of the randomised controlled
trails of zinc supplementation and pregnancy outcome is that
they lacked the sample sizes to detect diﬀerences [104].
Many of the zinc supplementation studies have been
conducted in developing countries where incidence of zinc
deficiency is high, and these women are often selected as
they are less well nourished or have low plasma zinc levels
[105, 106]; benefits of supplementation include reduced
incidence of pregnancy-induced hypertension or low birth
weights [105]. These studies do however suggest the benefits
of zinc supplementation in developing countries where zinc
deficiency is likely, although for developed countries there is
conflicting data as to the benefits [107–110].
Zinc deficiency has been associated with preeclampsia
since the 1980s [59, 92, 111] including adolescent pregnan-
cies [112]. Placental zinc concentration has also been shown
to be lower in preeclampsia in cross-sectional retrospective
studies with placental zinc values positively correlating with
birth weights [92, 113, 114]. More recently lower serum
concentrations of zinc in preeclampsia compared to controls
have been shown in two relatively small retrospective studies
from Turkey (mean± SD: 10.6± 4.4 versus 12.7± 4.1 μg/L,
resp.) [94, 115]; the authors suggested that this may be
useful for early diagnosis as lower plasma zinc concentrations
have been associated with increased lipid peroxidation in rat
studies [116]. Moreover, in a recent retrospective study in
India, reduced serum zinc concentrations in mild and severe
preeclamptic mothers compared to controls were reported;
the authors suggest that the reduction could not only eﬀect
the antioxidant protection but could also contribute to
the rise in blood pressure [117]. The lower serum zinc
concentrations in mothers who develop preeclampsia have
been suggested to at least be partly due to reduced oestrogen
and zinc binding-protein levels [118]. Zinc is transported
across the placenta via active transport from the mother
to the fetus [111]. Studies have shown that the fetus has
notably higher zinc concentrations compared to the mother,
even in cases of preeclampsia [111, 119], indicating that
the fetus, itself, can maintain adequate zinc homeostasis.
Amniotic fluid zinc concentrations have also been reported
to be decreased in preeclamptic women delivering preterm
(33- to 36-week gestation) in a small retrospective cross-
sectional study from the USA [59]. It must be noted that
as with all these micronutrients, the concentrations early
in pregnancy in relation to the development of pregnancy
complications remains to be established.
2.4. Manganese. Manganese is a free element in nature (often
in combination with iron); furthermore, manganese(II) ions
function as cofactors for a number of enzymes; the element is
thus a required trace mineral for all known living organisms.
Manganese is also an important cofactor for a number of
enzymes, including the antioxidant manganese superoxide
dismutase (Mn-SOD; Figure 2) which may protect the
placenta from oxidative stress by detoxifying superoxide
anions [120]. Dietary manganese is the main source of
exposure under normal circumstances; current requirements
for manganese, although less studied compared to other
micronutrients, are shown in Table 1 and little is known
about the eﬀects of deficiency or excess of manganese on
the developing human fetus or pregnancy outcome [121].
This is further hampered by the fact that at present sensitive
biomarkers of manganese exposure and nutritional status
are not available other than some estimates from blood
concentrations [121].
Circulating whole blood manganese concentrations have
been shown to be lower in women with fetal growth restric-
tion compared to healthy controls (mean± SD: 16.7± 4.8
versus 19.1± 5.9 μg/L, resp.) indicating that this micronutri-
entmay be important inmaintaining fetal growth [122]. This
study also found that manganese concentrations were higher
in umbilical samples from fetal growth restriction cases
compared to controls suggesting that manganese contributes
to diﬀerent eﬀects on birth weight in healthy mothers [122].
Zota et al. retrospective study in the USA reported a non-
linear relationship between manganese concentrations and
birth weights in a cohort of 470 full-term (delivered at >37-
week gestation) infant further indicating the potential aﬀect
on fetal growth [123]. A recent small retrospective study
of African-American mothers reported reduced umbilical
cord whole blood manganese concentrations in neonates
born to mothers with preeclampsia compared to controls
(mean (95% CI): 2.2 (1.5, 3.2) versus 3.7 (3.2, 4.2) μg/L,
resp.) [124]. Furthermore, this study found that like other
micronutrients umbilical cord blood from smoking mothers
had reduced manganese concentrations [124]. Than et al.
demonstrated increased fetal membrane MnSOD mRNA
expression in women with preterm labour [125]. Manganese
is one of the least studied micronutrients, and at present
no supplementation trial has been published which may
reflect the lack of data on manganese concentrations in
pregnancy.
2.5. Vitamins C and E. Vitamin C (ascorbic acid and
dehyroascorbic acid) is an essential water-soluble vitamin
found widely in fruit and vegetables; it has important roles
in collagen synthesis, wound healing, prevention of anaemia,
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and as an antioxidant as it can quench a variety of reactive
oxygen species and reactive nitrogen species in aqueous en-
vironments [126]. Vitamin C is commonly included in low
doses (<200mg/day) within multivitamin preparations for
pregnancy but has also been given in higher doses (up to
1000mg/day) as a supplement, alone or in combination
with vitamin E [127]. Smoking has been shown to increase
oxidative stress and metabolic turnover of vitamin C, thus
the requirement for smokers is increased by 35mg/day [79].
Vitamin E (α-tocopherol) is a lipid-soluble vitamin
acting with the lipid membrane and with synergistic interac-
tions with vitamin C [128] (Figure 3). Vitamin E functions
primarily as a chain-breaking antioxidant that prevents
propagation of lipid peroxidation [127, 129]. A considerable
interest exists regarding prevention of maternal and perinatal
morbidity with vitamins C and E. However, the most recent
meta-analysis of ten trials (6533 women) published in 2008
of antioxidant supplementation (including vitamin C and
E but also other supplements such as lycopene) showed no
diﬀerence in the relative risk (RR) of preeclampsia (RR 0.73,
95% CI 0.51 to 1.06), preterm birth (before 37 weeks) (RR
1.10, 95% CI 0.99 to 1.22), SGA infants (RR 0.83, 95% CI
0.62 to 1.11), or any baby death (RR 1.12, 95% CI 0.81 to
1.53) [7]. Considerable heterogeneity between the trials was
seen reflecting the diﬀerent supplements studied, the varying
risk criteria used for entry into the studies, and the study
sizes. A couple of subsequent recent multicentre double-
blinded randomised trials of a combination of vitamin C and
E [130, 131] also found that supplementation did not reduce
the rate of preeclampsia or gestational hypertension and, like
the Vitamins In Preeclampsia trial in 2006 [132], increased
the risk of fetal loss or perinatal death and preterm prelabour
rupture of membranes. Another recent multicentre placebo-
controlled trial of vitamin C and E in women with type-1
diabetes in pregnancy (DAPIT) also reported no diﬀerences
in the rates of preeclampsia between supplemented or
placebo groups [133]. Further investigations are required
as the concentrations of these vitamins remain significantly
reduced in women with preeclampsia, but in the absence
of further evidence, routine supplementation with higher
dose vitamin C and E is not recommended as they can be
potentially dangerous in high concentrations.
3. Adolescent Pregnancies
Another factor to highlight is that pregnancy in adolescent
women is a topic of increasing health concern in many
countries [134]. Pregnant adolescents are of a greater
nutritional risk as they themselves are undergoing an intense
process of growth and development [135]. It has been
suggested that there is competition for nutrients between
a pregnant adolescent and her fetus, as both are in critical
stages of growth during the gestational period [65, 136].
As mentioned throughout above, micronutrient deficiencies
have been associated with adolescent pregnancies [66, 87,
112]. The recent About Teenage Eating study showed that
teenage pregnancy in the UK is associated with decreased
Ascorbate •
e •
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α-tocopherol
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Figure 3: Synergistic mechanisms of vitamin C (ascorbate) and
vitamin E (α-tocopherol) to prevent lipid peroxidation. O2•: oxygen
free radical.
consumption of micronutrients and that this is associated
with an increased risk of SGA infants [65].
Low micronutrient intake poses a health risk to suc-
cessful pregnancy in the UK, especially in adolescence.
Socioeconomic deprivation in the UK population has been
shown to be an independent risk factor for eating less fruit
and vegetables and also for increased smoking, which is
known to cause further depletion of micronutrients [137].
Although attempts are being made to persuade women of
low socioeconomic status of the importance of a balanced
diet, the central roles that fruit and vegetables have in this
and that healthy food can be low cost and convenient, this is
often met with resistance [138].
The increase in pregnancies in mothers of older ages
highlights another subgroup at increased risk of pregnancy
complications. We are not aware of any studies at present
examining this important group, and future investigations
are required especially as some of these micronutrient
concentrations decline with increasing age.
4. Conclusions
Increased knowledge about the importance of these specific
antioxidant micronutrients and the crucial part that they
have in maintaining successful pregnancy and determining
both the long- and short-term health of both mother and
baby needs to be addressed and made a key focus for
future health strategies in improving pregnancy outcomes.
This is particularly important with regards to preeclampsia
and fetal growth restriction, where oxidative stress is an
essential component to the aetiology of these conditions
and so these specific antioxidant micronutrient deficiencies
may play a contributing role. Only by fully understanding
the requirements for micronutrients during pregnancy will
we be able to evaluate the potential use of these dietary
antioxidant supplements as a way of preventing pathological
pregnancy outcomes. However, it must also be remembered
that these antioxidant and other micronutrients can be
obtained via a healthy diet thereby negating the need for
supplementation. Future strategies focussing on providing
nutritional guidance specifically to pregnant women will be
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pivotal in helping to ensure optimal health of both mother
and baby.
Key Messages
(1) Further research is needed to accurately quantify
levels of micronutrients in pregnancy and how levels
vary over the course of pregnancy.
(2) The actions of antioxidant micronutrients on mater-
nal, fetal, and placental health needs to further
elucidated.
(3) Prenatal guidance needs to be made clear to ensure
that women and practitioners are aware of the
nutritional requirements during pregnancy and how
healthy diet can prevent diseases of pregnancy.
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